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Abstract We have studied the effect of ectopie overexpression 
of a ras gene on the expression of the other two members of the 
ras gene family. We obtained NIH3T3 cell lines stably 
transfected with inducible H-ras and N-ras oncogenes. The 
expression of these genes is driven by a glucocorticoid-responsive 
promoter and the addition of dexamethasone resulted in a 
dramatic induction (10-20-fold) of H- or N-ras mRNA, peaking 
4 h after hormone addition. The induction of the expression of 
ras oncogenes resulted in a transformed phenotype. In quiescent 
NIH3T3 cells transfected with inducible H-ras oncogenes, the 
induction of H-Ras was followed 12 h later by a 3-fold increase in 
the mRNA expression of endogenous K-ras and N-ras. Similarly, 
in NIH3T3 transfected with inducible N-ras oncogene, the 
induction of N-ras was followed by an increase in the expression 
of endogenous K- and H-ras genes. Interestingly, the effect was 
not limited to the mutated N-ras, as a similar result was obtained 
in cells transfected with N-ras proto-oncogene. The induction of 
ras genes expression was not linked to cell cycle progression as it 
was reproduced in cells arrested in S-phase by pretreatment with 
hydroxyurea. These results suggest the presence of a positive 
cross-regulation in the expression among the members of the Ras 
family. This effect could play a role in Ras-mediated carcinogen-
esis. 
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and N-Ras proteins into quiescent fibroblasts stimulates 
DNA synthesis [6-8] and microinjection of anti-p21 neutraliz-
ing antibody or dominant inhibitory Ras mutant proteins in-
hibits the stimulation of DNA synthesis induced by growth 
factors or phorbol esters [9-11]. (ii) Mitogenic stimulus elic-
ited by growth factors or serum results in a rapid increase in 
the fraction of GTP-bound p21 [12]. (iii) We and others have 
previously demonstrated that the expression of the three ras 
genes is up-regulated upon mitogenic stimulation of fibro-
blasts [13-15]. Therefore, the increased activity of Ras pro-
teins by growth factors is due to two factors: increased bio-
chemical activity (a higher fraction of GTP-bound Ras) and 
increased levels of Ras proteins. 
Despite the amount of work carried out on ras function, the 
expression of ras proto-oncogenes has received little attention. 
In this work we have explored the possibility that a Ras pro-
tein could modify the expression of the other ras genes. 
2. Materials and methods 
NIH3T3 cells were obtained from ATCC and were cultured in 
Dulbecco's modified Eagle's medium (DMEM) (Gibco) supplemented 
with 10% newborn calf serum (Biochrom) and 80 μg of gentamycin 
1. Introduction 
The mammalian ras gene family is composed of three mem-
bers: H-, K-, and N-ras, that encode highly related 21 kDa 
proteins, termed p21s. The three proteins are almost identical 
except for the last 20 amino acids. p21s are membrane-asso-
ciated proteins and bind and hydrolyze GTP [1,2]. Mutated 
forms of ras genes in codons 12, 13 or 61 are present in a 
significant fraction of human and experimental tumors. These 
mutants are constitutively in the activated (GTP-bound) state 
[3,4]. Ras-GTP but not the inactive form Ras-GDP interacts 
with a series of effectors, namely Raf, PI3 kinase and 
RalGDS, which mediate signal transduction towards the nu-
clei through different pathways [5]. 
There is ample evidence that Ras are involved in the control 
of cell proliferation: (i) Microinjection of oncogenic H-Ras 
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Fig. 1. A: Schematic representation of pDxHras. The boxes from 
left to right represent the MMTV LTR promoter (inducible by glu-
cocorticoids), 2.9 kb from the human H-ras oncogene (black boxes 
indicate exons), the SV40 early promoter (SV), the neomycin/G418 
resistance gene (neo), the SV40 early polyadenylation signal (pA) 
and sequences derived from pBR322, containing the ß-lactamase 
gene. The total size of pDxHras is 11.3 kb. B: Phase-contrast mi-
crographs of ЗТЗ-DxHT cells untreated (right) and treated with 0.5 
μΜ dexamethasone for three days (left). Original magnification: 
X100. 
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Fig. 2. A: Expression of ras genes in quiescent ЗТЗ-DxHT cells after dexamethasone addition. Cells were grown to confluence, and the medium 
was replaced with DMEM containing 0.5% calf serum. After 72 h dexamethasone was added to a concentration of 0.5 μΜ. Total RNA was 
isolated at the indicated times and analyzed by Northern hybridization. The same filter was consecutively hybridized to the indicated probes. 
Arrowheads signal the position of 28S and 18S rRNA. The arrow indicates the position of the exogenous H-ras transcript. A photograph of 
the filter after transfer is shown to assess loading and integrity of RNAs. Exposure times were 3 h for the H-ras hybridization and 3 days for 
K- and N-ras. В : Relative expression of ras gene mRNA. The intensity of the signals of ras transcripts from the Northern blot of A was deter-
mined by densitometric analysis. The graph represents the expression of the smaller mRNA of ras genes normalized with respect the 18S 
rRNA. The highest expression for each gene was taken as 100% value. 
per ml. To construct the plasmid pDxHras, a 2.9 kb Sacl genomic 
fragment from human T24 oncogene (plasmid pT24-C3 [16]) was first 
cloned into the Sacl site of pUC1813 [17]. The fragment Sail of the 
resultant plasmid containing H-ras was cloned in the Sail site of the 
polylinker of pMAMneo (Clontech). The resulting plasmid, pDxHras, 
expresses the human H-ras oncogene (mutated in codon 12) under the 
control of the mammary tumor virus long terminal repeat (MMTV 
LTR), inducible by dexamethasone (Fig. 1A). Plasmid pDxNras con-
tains murine N-ras oncogene (mutated in codon 61) inducible by 
dexamethasone. It was constructed by cloning a Smal-Pstl fragment 
containing the MMTV LTR and N-ras oncogene from the plasmid 
pMMTV-N-ras [18] into the BamHl site of the vector pNeo3, which 
carries the G418-resistance gene [19] (Fig. 4A). The plasmid pDxNras/ 
N is the equivalent to pDxNras but carrying the normal murine Ή-ras 
proto-oncogene and with the MMTV LTR-N-ras fragment inserted in 
the opposite orientation into pNeo3. Transfections were carried out 
by electroporation (Bio-Rad Gene Pulser, 300 V, 0.5 mF) and trans-
fected cells were selected with G418 (400 μ^piύ). Individual colonies 
were picked and expanded. Total RNA was isolated from cells by the 
acid guanidine thiocyanate method [20]. Northern blots were prepared 
and hybridizations were carried out essentially as described [14]. The 
probes for murine H-, K- and Ή-ras and for human H-ras genes were 
as described [14]. Semi-quantitative determination of mRNA levels 
was carried out by densitometric reading of short exposure films 
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with a HP ScanJet Plus densitometer and Quantiscan program (Bio-
soft). Filters were consecutively hybridized to different probes and 
signals from the previous hybridization were stripped out by boiling 
the filters for 5 min in water. Immunoblots were performed as de-
scribed using anti-N-Ras antibody (Oncogene Science) [14]. 
3. Results and discussion 
We constructed an expression vector, termed pDxHras 
which contains the human H-ras oncogene (Val 12 mutant) 
under the control of MMTV promoter and the G418-resist-
ance gene, which is schematically depicted in Fig. 1A. 
pDxHras was transfected by electroporation into NIH3T3 
and several G418-resistant clones were analysed for H-ras 
mRNA overexpression after addition of 0.5 mM dexametha-
sone. A clone showing a clear H-ras mRNA induction and 
transformed phenotype after drug addition, termed 3T3-
DxHT (for transforming H-ras), was selected for further stud-
ies. ЗТЗ-DxHT cells exhibited a transformed phenotype when 
growing in the absence of added dexamethasone, a finding 
due to the well documented leakiness of the MMTV pro-
moter. However, after addition of the hormone (0.5 μΜ, 3 
days) the cells showed a markedly transformed phenotype 
with formation of numerous foci (Fig. IB). To study ras genes 
induction, ЗТЗ-DxHT cells led to quiescence by incubation for 
48 h with medium containing 0.5% calf serum. This treatment 
reduced the levels of endogenous ras mRNA levels [15]. The 
cells were then treated with 0.5 μΜ dexamethasone and RNA 
was prepared after different times of treatment. The expres-
sion of the three members of the Ras family is shown in Fig. 
2A. As expected, H-ras expression was rapidly and dramati-
cally induced by dexamethasone. The exogenous H-ras tran-
script can be distinguished from the endogenous one by its 
larger size. The maximum level of H-ras mRNA was detected 
4 h after hormone addition. To study the expression of the 
other ras genes we reprobed the Northern blot with specific 
murine K- and N-ras probes. Interestingly, the expression of 
endogenous K-ras and N-ras genes was also clearly induced 
8-14 h after the peak of H-ras mRNA, i.e. 12-18 h after 
hormone induction (Fig. 2A). Densitometric analysis of the 
films and rRNA compared with the rRNA present in the 
filters revealed a maximal induction 3.5-fold and 2.5-fold for 
K-ras and N-ras respectively (Fig. 2B). To rule out a possible 
effect of dexamethasone on the regulation of ras genes in 
NIH3T3 cells, we determined the mRNA levels of the three 
ras genes after dexamethasone addition to arrested NIH3T3 
cells. As shown in Fig. 3, the treatment of NIH3T3 cells with 
1 μΜ dexamethasone did not result in any increase in the 
mRNA levels of H-, K- and N-ras genes. Therefore we con-
clude that the up-regulation of N- and K-ras in ЗТЗ-DxHT 
cells was not due to the hormone but to ras gene expression. 
Some reports suggest that there are differences in the bio-
chemical activities of the three ras genes [21-23]. To study 
whether the effect described above with H-ras was reproduced 
with another ras gene, we transfected NIH3T3 cells with 
pDxNras, an expression vector carrying an inducible murine 
N-ras oncogene (mutated at codon 61) (Fig. 4A). After trans-
fection and selection with G418, we selected a cell clone 
termed ЗТЗ-DxNT (for transforming N-ras). As in the case 
of H-ras-transfected cells, the ЗТЗ-DxNT cells in the absence 
of dexamethasone also showed a more transformed morphol-
ogy than parental cells, but the addition of dexamethasone 
resulted in a dramatic enhancement of this phenotype (Fig. 
4B). The treatment of quiescent ЗТЗ-DxNT cells with 0.5 μΜ 
Fig. 3. Expression of ras genes in NIH3T3 after the indicated times of exposure to 1 μΜ dexamethasone. The experiment was performed as de-
scribed in the legend to Fig. 1. 
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Fig. 4. A: Schematic representation of pDxNras. The boxes from 
left to right represent the MMTV LTR promoter inducible by glu-
cocorticoids, 7.1 kb from the murine N-ras oncogene mutated in co-
don 61 (black boxes indicate exons), the herpes thymidine kinase 
promoter (TK), the neomycin/G418 resistance gene (neo), the herpes 
thymidine kinase polyadenylation signal (pA) and sequences derived 
from pBR322, containing the ß-lactamase gene. The total size of 
pDxNras is 13.2 kb. B: Phase-contrast micrographs of 3T3-DxNT 
cells untreated (right) and treated with 0.5 μΜ dexamethasone for 
three days (left). Original magnification: X100. C: Phase-contrast 
micrographs of ЗТЗ-DxNN cells untreated (right) and treated with 
0.5 μΜ dexamethasone for three days (left). Original magnification: 
X100. 
dexamethasone resulted in a rapid overexpression of murine 
N-rai mRNA (Fig. 5A). This was confirmed at the protein 
level by immunoblot, using a specific anti-N-Ras antibody 
(Fig. 5C). Reprobing of the Northern blot with H- and K-
ras probes revealed that the mRNA expression of these genes 
also increased, peaking 20 h after hormone addition. The in-
crease in the expression of these genes (normalized with re-
spect to rRNA amount), was about 5-fold, as determined by 
film densitometry (Fig. 5B). Thus, ectopie overexpression of 
N-ras oncogene reproduced the effect observed for H-ras, i.e. 
an augmented mRNA level of the other two ras genes. 
In order to know whether the cross-regulation of ras can 
also be induced by a normal ras gene, we obtained NIH3T3 
cells transfected with the plasmid pDxNras/N, which encodes 
the inducible normal murine N-ras proto-oncogene. We chose 
a transfected cell line, ЗТЗ-DxNN (for normal N-ras). These 
cells were not transformed, although they showed some trans-
formed morphology upon dexamethasone addition (Fig. 4C). 
This finding is in agreement with the transforming effect of the 
overexpression of N-ras proto-oncogene in vitro [24] and in 
vivo [25]. In ЗТЗ-DxNN cells we also observed an up-regula-
tion of the endogenous ΐί-ras and K-ras genes, thus reproduc-
ing the results obtained with cells transfected with the acti-
vated N-ras gene (Fig. 6A). Densitometric analysis revealed 
an increase of 10-fold for K-ras and 3-fold for H-ras, normal-
ized to rRNA amount (Fig. 6B). It is noteworthy that the 
dexamethasone-induced expression of exogenous normal N-
ras did not decline as rapidly as mutated H-ras (Fig. 6A) 
and mutated N-ras (Fig. 2A). This difference has been previ-
ously described for normal and mutated H-ras and explained 
as an oncogene-mediated repression of MMTV LTR, 
although the mechanism for this effect remains unclear [26]. 
The results of this work show that overexpression of a 
particular ras gene up-regulate the expression of the other 
two ras genes, peaking 18-20 h after dexamethasone addition. 
In the three transfectant cell lines studied, the highest up-reg-
ulation was observed for the endogenous K-ras gene. In all 
systems tested, including NIH3T3, there is a correlation be-
tween levels of ras mRNA and protein, and therefore we 
suggest this is also the case in our transfectants. Commercial 
antibodies specific for Ras proteins tested by us showed some 
cross-reactivity among them, making difficult to confirm the 
former hypothesis. We do not know the mechanism by which 
Ras exerts this up-regulation of the other gene family mem-
bers. Further work is required to establish whether it is due to 
an increase in gene transcription or in the stability of ras 
mRNA. 
We and others have shown that serum stimulation of qui-
escent cells results in up-regulation of ras genes peaking in late 
Gl-phase [13-15]. Therefore, the results presented here with 
the inducible ras genes could be explained if the overexpres-
sion of a ras gene provokes the transit from quiescence to 
proliferation which in turn would increase the expression of 
the other two ras genes. However, the data do not exclude the 
possibility that the overexpression of a particular ras gene 
induces the expression of the other members of the ras family 
through a pathway independent of cell cycle progression. To 
explore this latter possibility we induced Ras expression by 
dexamethasone in ЗТЗ-DxHT cells previously treated with 
hydroxyurea, a DNA synthesis inhibitor. In these conditions, 
cell cycle progression is abolished. As shown in Fig. 7, an 
increase of N- and K-ras mRNA is detected 12 h after hor-
mone addition in the absence of serum and in the presence of 
hydroxyurea. As expected, DNA synthesis was undetected by 
thymidine incorporation assays (not shown). Although this 
possibility cannot be formally excluded, the former results 
are consistent with the idea that H-Ras protein can induce 
the expression of the other two ras genes by a mechanism 
not linked to DNA synthesis and cell cycle progression. 
Many animal and human tumors with activation of ras 
genes show overexpression of mutated [27-29] or normal ras 
genes [30-33]. In the present work we have found an auto-
regulatory positive effect on the expression of the ras gene 
family. To our knowledge this is the first report of a regula-
tory interaction between ras genes. It is noteworthy that this 
effect has been observed both for mutant and normal N-ras 
genes, as well as for H-ras oncogene. Thus, these results sup-
port the hypothesis that the overexpression of a ras gene in 
tumors may contribute to carcinogenesis by increasing in turn 
the expression of the other ras genes. 
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Fig. 5. A: Expression of the ras genes in quiescent ЗТЗ-DxNT cells after dexamethasone addition. The experiment was performed as described 
in the legend to Fig. 1. Exposure times were 6 h for the N-ras hybridization and 5 and 7 days for H- and K-ras respectively. The vector used 
expressed several N-ras transcripts and the signal of the most abundant are also present in the K-ras hybridization, due to an incomplete re-
moval of the signals after the hybridization with N-ras probe. В : Relative expression of the ras genes determined by densitometry, as indicated 
in the legend to Fig. 1. C: Accumulation of p21-N-Ras protein after the addition of dexamethasone to ЗТЗ-DxNT determined by immunoblot 
with a specific anti-N-Ras antibody. The right lane contains bacterially expressed p21(Val-12) as a positive control. The mobility of this protein 
is lower than N-Ras. 
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Fig. 6. A: Expression of the ras genes in quiescent ЗТЗ-DxNN cells after dexamethasone addition. The experiment was performed as described 
in the legend to Fig. 1. Exposure times of the filters were 8 h for the N-ras hybridization and 4 and 5 days for H- and K-ras respectively. 
B: Relative expression of the ras genes determined by densitometry as indicated in the legend to Fig. 1. 
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